Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Emory University patents legumain inhibitors

Dec. 23, 2020

Phase III DOM-INNATE trial of SGX-942 does not show statistically significant benefit

Dec. 23, 2020

DTRM-555 meets primary endpoint in first-in-human study with patients with B-cell lymphomas

Dec. 22, 2020

Menin/KMT2A inhibitor KO-539 shows encouraging preliminary results for treating R/R AML

Dec. 22, 2020

Celgene synthesizes new CKI-alpha degradation inducers

Dec. 22, 2020

FDA approves Xpovio for multiple myeloma after at least one prior therapy

Dec. 21, 2020

LACEWING study of Xospata in FLT3mut+ AML does not meet primary endpoint

Dec. 21, 2020

FDA approves Orgovyx for advanced prostate cancer

Dec. 21, 2020

Tumors, metastases activate mTOR in different ways

Dec. 21, 2020

Preliminary phase I/II data for ZN-c5 monotherapy in ER-positive/HER2-negative breast cancer

Dec. 21, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Combination locked out in ATTR-CM? ‘Dead,’ expert says
BioWorld
The synergy – or lack of it – between knockdown drugs and stabilizers in treating transthyretin (TTR)-mediated amyloid cardiomyopathy (ATTR-CM) became one of the...